O2PR

O2PR is a specialist PR and communications consultancy providing bespoke services to public and private sector organisations operating in the fields of science, engineering and technology. The de...

Management of complications

Pain management

Perioperative Management

Management of Adverse Effects

FDA issues complete response for Lymphoseek

Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB) said late Monday that FDA issued a complete response letter for Lymphoseek tilmanocept for use in intraoperative lymphatic imaging. According to Navidea,...

Biotech Stock Mailbag: Navidea, Celsion, Raptor and Threshold

BOSTON (TheStreet) -- This week's Biotech Stock Mailbag is open for business. @shakes2222 asks, "Why no follow-up after Navidea's conference call yesterday Tuesday? Do you have an opinion on FDA appro...

Navidea: Interesting Biotech Story Gets Even More Dramatic

By Mike Williams: In early August, I wrote an article discussing the investment thesis for Navidea Biopharmaceuticals (NAVB). My main warning to prospective and active investors in the stock was to ma...

FDA approves Lymphoseek for lymph node mapping

The FDA has approved Navidea Biopharmaceuticals' radioactive tracer Lymphoseek for breast cancer and melanoma intraoperative  -More- 

Navidea Biopharmaceuticals Receives Complete Response Letter from FDA for Lymphoseek NDA Due to ...

CRL Unrelated to Lymphoseek® Efficacy and Safety Data Conference Call Scheduled for 4:45 p.m. ET September 10, 2012

FDA Approves Navidea's Lymphoseek® Injection for Use in Lymphatic Mapping

Navidea Biopharmaceuticals Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced U.S. Food and Drug Administration (FDA) approval of Lymphoseek® (techn...

Navidea seeking EU approval for Lymphoseek

Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB) submitted an MAA to EMA for Lymphoseek tilmanocept for use in intraoperative lymphatic imaging. Navidea said the MAA covers the use of Lymphoseek for gene...

Navidea Takes A Kicking Despite Lymphoseek Approval

By EP Vantage:U.S. approval of the cancer tracer Lymphoseek, granted on Wednesday, came as something of a surprise given a previous rejection and an approval decision date some six weeks off. But th...

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.

We have investigated the effects of short-term neoadjuvant and long-term androgen deprivation therapies (ADTs) on beta-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) expressi...

Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.

Beta-microseminoprotein (MSP)/MSMB is an immunoglobulin superfamily protein synthesized by prostate epithelial cells and secreted into seminal plasma. Variants in the promoter of the MSMB gene have be...

Optimal Exploitation for a Commercial Fishing Model.

A two non-linear dynamic models, first one in two state variables and one control and the second one with three state variables and one control, are presented for the purpose of finding the optimal co...

Fast (18)f labeling of a near-infrared fluorophore enables positron emission tomography and optical imaging of sentinel lymph nodes.

We combine a novel boronate trap for F(-) with a near-infrared fluorophore into a single molecule. Attachment to targeting ligands enables localization by positron emission tomography (PET) and near-i...

Slipped capital femoral epiphysis: diagnosis and management.

Slipped capital femoral epiphysis is the most common hip disorder in adolescents, and it has a prevalence of 10.8 cases per 100,000 children. It usually occurs in children eight to 15 years of age, an...